Investigations and studies about CAR-T cell therapy in conjunction with other novel targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitor, programmed cell death protein 1 (PD-1) antibody revealed synergistic action for relapsed/refractory (R/R) DLBCL (6–8). This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.